Skip to main content

Advertisement

SpringerLink
Log in

Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The gene encoding MAP30 protein was cloned from bitter melon and recombinant MAP30 was expressed and purified. The human hepatoma G2.2.15 cells were exposed to different concentrations of MAP30. MTT assay was used to evaluate the cytotoxicity of the drugs and real-time PCR and Southern hybridization were applied to quantify extracellular HBV DNA and replicative intermediates intracellular and cccDNA in nucleus. HBsAg and HBeAg were assessed by enzyme-linked immunosorbent assay (ELISA). The results showed that exposure of HepG2.2.15 cells to MAP30 resulted in inhibition of HBV DNA replication and HBsAg secretion. After exposed to three different concentrations of MAP30 for 2, 4, 6, and 8 days respectively, the inhibition rates of extracellular HBV DNA, HBsAg, and HBeAg of each concentration decreased significantly (P < 0.05). After 9 days of treatment, the inhibition rates of extracellular HBV DNA of the different concentrations differed greatly (P < 0.001). The MAP30 could inhibit the production of HBV (P < 0.01) dose-dependently. The expression of HBsAg was significantly decreased by MAP30 dose-dependently (P < 0.001) and time-dependently (P < 0.001). Lower dose of MAP30 (8.0 μg/ml) could inhibit the expression of HBsAg and HBeAg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Fleming J (2002) Current treatments for hepatitis. J Infus Nurs 25:379–382

    Article  PubMed  Google Scholar 

  2. Elsaadany S, Tepper M, Mao Y, Semenciw R, Giulivi A (2002) An epidemiologic study of hepatocellular carcinoma in Canada. Can J Public Health 93:443–446

    PubMed  Google Scholar 

  3. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213

    Article  PubMed  CAS  Google Scholar 

  4. Torbenson M, Thomas DL (2002) Occult hepatitis B. Lancet Infect Dis 2:479–486

    Article  PubMed  Google Scholar 

  5. Hino O, Kajino K, Umeda T, Arakawa Y (2002) Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 37:883–887

    Article  PubMed  CAS  Google Scholar 

  6. Esteban R (2002) Management of chronic hepatitis B: an overview. Semin Liver Dis 22(Suppl 1):1–6

    Article  PubMed  Google Scholar 

  7. Mazumdar TN (2001) Management of chronic hepatitis B infection: an update. J Indian Med Assoc 99:306–308

    PubMed  CAS  Google Scholar 

  8. Ganem D, Varmus HE (1987) The molecular biology of the hepatitis B viruses. Annu Rev Biochem 56:651–693

    Article  PubMed  CAS  Google Scholar 

  9. Wai CT, Chu CJ, Hussain M, Lok AS (2006) HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36:1425–1430

    Google Scholar 

  10. Manns MP (2002) Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis 22(Suppl 1):7–14

    Article  PubMed  Google Scholar 

  11. Shindo M, Hamada K, Koya S, Sokawa Y, Okuno T (1999) The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 94:2237–2245

    Article  PubMed  CAS  Google Scholar 

  12. Liaw YF (2002) Therapy of chronic hepatitis B: current challenges and opportunities. J Viral Hepat 9:393–399

    Article  PubMed  Google Scholar 

  13. Wolters LM, Hansen BE, Niesters HG, de Man RA (2002) Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudineganciclovir. Eur J Gastroenterol Hepatol 14:1007–1011

    Article  PubMed  CAS  Google Scholar 

  14. Chiou HC, Lucas MA, Coffin CC, Banaszczyk MG, Lollo CP (2001) Gene therapy strategies for the treatment of chronic viral hepatitis. Expert Opin Biol Ther 1:629–639

    Article  PubMed  CAS  Google Scholar 

  15. Lee-Huang S, Huang PL, Huang PL (1995) Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31[J]. Proc Natl Acad Sci U S A 92(19):8818–8822

    Article  PubMed  CAS  Google Scholar 

  16. Lee-Huang S, Huang PL, Chen HC, Huang PL, Bourinbaiar A, Huang HI, Kung HF (1995) Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 161(2):151–156

    Article  PubMed  CAS  Google Scholar 

  17. Zarling DA, Calhoun CJ, Feuerstein BG, Sena EP (1990) Cytoplasmic microinjection of immunoglobulin Gs recognizing RNA helices inhibits human cell growth. J Mol Biol 211(1):147–160

    Article  PubMed  CAS  Google Scholar 

  18. Tumer NE, Hwang DJ, Bonness M (1997) C-terminal deletion mutant of pokeweed antiviral protein inhibits viral infection but does not depurinate host ribosomes. Proc Natl Acad Sci U S A 94(8):3866–3871

    Article  PubMed  CAS  Google Scholar 

  19. Lee-Huang S, Huang PL, Nara PL, Chen HC, Kung HF, Huang P, Huang HI, Huang PL (1990) MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett 272(1–2):12–18

    Article  PubMed  CAS  Google Scholar 

  20. Joyeux A, Cavaillès V, Balaguer P, Nicolas JC (1997) RIP 140 enhances nuclear receptor-dependent transcription in vivo in yeast. Mol Endocrinol 11(2):193–202

    Article  PubMed  CAS  Google Scholar 

  21. Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19(6):622–638

    PubMed  CAS  Google Scholar 

  22. Garson JA, Grant PR, Ayliffe U, Ferns RB, Tedder RS (2005) Real-time PCR quantitation of hepatitis B virus DNA using automated sample preparation and murine cytomegalovirus internal control. J Virol Methods 126(1–2):207–213

    Article  PubMed  CAS  Google Scholar 

  23. von Weizsacker F, Kock J, Wieland S, Offensperger WB, Blum HE (1990) Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis. Hepatology 30:308–315

    Article  Google Scholar 

  24. von Weizsacker F, Wieland S, Kock J, Offensperger WB, Offensperger S, Moradpour D, Blum HE (1997) Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 26:251–255

    Article  Google Scholar 

  25. Chu CK, Boudinot FD, Peek SF, Hong JH, Choi Y, Korba BE, Gerin JL, Cote PJ, Tennant BC, Cheng YC (1998) Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 3:113–121

    PubMed  CAS  Google Scholar 

  26. Colacino JM (1996) Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU). Antiviral Res 29:125–139

    Article  PubMed  CAS  Google Scholar 

  27. Pollicino TL, Belloni G, Raffa N, Pediconi G, Squadrito G, Raimondo Levrero M (2006) Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130(3):823–837

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Laboratory of Toxicology, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China

    Jian Ming Fan, Qiao Zhang & Yu Bao Xu

  2. School of Life Sciences, Henan Agricultural University, Zhengzhou, 450002, China

    Jun Xu

  3. Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China

    Sha Zhu

  4. School of Life Sciences, NanYang Normal University, NanYang, 473061, China

    Tao Ke

  5. College of Basic Medical Sciences, Henan Institute of Traditional Chinese Medicine, Zhengzhou, 450008, China

    De Fu Gao

Authors
  1. Jian Ming Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sha Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tao Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. De Fu Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu Bao Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian Ming Fan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fan, J.M., Zhang, Q., Xu, J. et al. Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon. Mol Biol Rep 36, 381–388 (2009). https://doi.org/10.1007/s11033-007-9191-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-007-9191-2

Keywords

Search

Navigation